Anavex Reports Animal Study Results as Lead Alzheimer's Compound Approaches Phase 1 Clinical Trials
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) reports promising results from animal studies with ANAVEX 2-73, the company's lead compound for the treatment and modification of Alzheimer's disease. ANAVEX 2-73 is the first of a new class of drugs that target mitochondrial dysfunction thought to be caused by oxidative stress to modify Alzheimer's disease.
Read more ...
The IT @ Networking Awards 2010
The goal of the IT @ Networking Awards 2010 (IT @ 2010), is to honour and promote outstanding healthcare IT solutions. The core aim of IT @ 2010 is to learn from the achievements of the very best IT installations on the globe. Healthcare systems face unprecedented challenges: high-tech, high-cost medicine; ageing populations; increased patient mobility; staff shortages; and a financial crisis. Intelligent IT solutions increase cost-effectiveness, productivity and safety and help healthcare facilities to confront these problems.
Read more ...
Scientists drive cancer genome decoding initiative
A pioneering plan unveiled by the International Cancer Genome Consortium (ICGC) will give scientists the ammunition they need to fight human cancer. The genomes from 25,000 cancer samples will be decoded and a data resource will be established with access provided to all cancer researchers. Writing in the journal Nature, the researchers of this strategy also highlight the importance of how projects in the EU and abroad are making significant contributions to cancer-fighting efforts.
Read more ...
Long-term efficacy and tolerability of Vimpat® (lacosamide)
UCB's antiepileptic drug (AED) Vimpat® (lacosamide) featured in several studies and analyses presented at the 62nd annual American Academy of Neurology (AAN) meeting. These data offer additional clinical evidence supporting the use of lacosamide as adjunctive therapy in the treatment of adult patients with partial-onset seizures.
Read more ...
Brain chemistry breakthrough in focal epilepsy
New research has shown that focal epilepsy occurs when brain cells called astroglia are activated causing nearby neurons to generate an epileptic discharge. The findings may lead to a new research direction for neurologists studying the origins of epilepsy and seeking new drug therapies. The study, funded in part by the EU, is published in the Public Library of Science (PLoS) Biology journal.
Read more ...
Collaborative project extends Rhenovia's innovative CNS biosimulation platform to study of epilepsy
Rhenovia Pharma SAS, a biopharmaceutical company specialized in the development of technologies to optimize the discovery and development of drugs for Alzheimer's and other diseases of the central and peripheral nervous system, has been named leader of RHENEPI, a EUR 2.5 million (USD 3.75M) project. The goals of RHENEPI are to develop and obtain experimental validation for an epilepsy biosimulation platform that can be used for the discovery of new antiepileptic drugs and the optimization of existing drugs.
Read more ...
EU-funded study investigates kidney regeneration potential
A paper published in The Lancet journal, as part of a series on renal medicine, has questioned if kidney regeneration may be possible in human beings as it is in fish and other lower vertebrates. The work is part of an ongoing EU-funded research project on the possibilities of kidney regeneration, and was carried out by a team from the Mario Negri Institute for Pharmacological Research in Bergamo, Italy.
Read more ...